Trial Profile
Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinal oedema
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2017 New trial record